Cumberland Pharmaceuticals (CPIX) — Who's Buying and Selling (13F, Q2 2026)

CPIX ranks #7252 out of 37696 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

CPIX is a disclosed holding of Jim Simons (Renaissance Technologies), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

33 institutions disclose a position in CPIX, but none treat it as a major bet — even Ikarian Capital, LLC, its most concentrated holder, allocates just 0.3% of its own portfolio to it.

CPIX reported a net loss of $10.9M over the trailing twelve months.

• Not yet profitable — net loss of $10.9M over the trailing twelve months
• Revenue declined 5.2% year over year
• Net income declined year over year, from -$2.9M to -$10.9M
• Generated $4.9M in positive operating cash flow
• Current ratio of 1.01x — below the conventional 1.5x liquidity buffer
• Liabilities run 2.10x equity — a highly leveraged balance sheet worth noting